Compare ResMed Inc. (RMD) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Weibo Corp — how do they compare? ResMed Inc. trades at $224.32 (market cap $32.61B), while Weibo Corp trades at $7.75 (market cap $1.93B). The key difference: ResMed Inc. is far larger — about 16.9× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (7.75%). Which is the better fit depends on your goals.
| RMD | WB | |
|---|---|---|
Market Cap | $32.61B | $1.93B |
Sector | Health | Media |
52-Week High | $293.73 | $12.83 |
52-Week Low | $182.82 | $7.20 |
Enterprise Value | $31.97B | $1.20B |
Dividend Yield | 1.17% | 7.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Weibo (WB) trades at $7.98, up 0.5% with neutral technical signals. The stock shows compelling valuation metrics including a P/E of 5.5 and P/B of 0.5, trading below balance sheet value. Recent quarters show earnings misses but strong profitability with 21.15% net margin. Cash flow trends improved in 2025 with $408M net inflow, while revenue remains stable at $1.76B.
WB presents value opportunity with deep discount to fundamentals, though competitive pressures and recent earnings misses warrant caution. Analyst consensus leans bullish with 45% buy ratings, but structural challenges in user engagement and AI monetization create headwinds. The 8% dividend yield provides downside protection while investors await growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
